You are here

  • Home
  • Archive
  • Volume 15, Issue 6
  • A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

Article metrics

Article menu
Download PDFPDF
Original Article
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

 

Online download statistics by month:

Online download statistics by month: February 2019 to November 2024

AbstractFullPdf
Feb 2019400
Mar 20191201
Apr 20193903
May 20192201
Jun 20192500
Jul 20191200
Aug 20192302
Sep 20191000
Oct 20191301
Nov 2019700
Dec 20191201
Jan 20201701
Feb 20202203
Mar 20201703
Apr 20201101
May 20202003
Jun 20201000
Jul 20201700
Aug 2020400
Sep 20201703
Oct 2020800
Nov 2020901
Dec 20201100
Jan 2021900
Feb 20211400
Mar 20212101
May 2021100
Jun 2021001
Jul 2021200
Aug 2021101
Oct 20212801
Nov 2021502
Dec 20211803
Jan 20221801
Feb 20222302
Mar 20222006
Apr 20225904
May 20224100
Jun 20224002
Jul 20221500
Aug 20224402
Sep 20224701
Oct 20226403
Nov 20225604
Dec 20221500
Jan 20232901
Feb 202310402
Mar 20231400
Apr 2023800
May 20233001
Jun 20231803
Jul 20232800
Aug 20235301
Sep 20232402
Oct 20234503
Nov 20232700
Dec 20233400
Jan 2024800
Feb 20241900
Mar 20241000
Apr 20241100
May 20242901
Jun 20244400
Jul 20242800
Aug 20244401
Sep 20242100
Oct 20242301
Nov 20241701
Total1551075